XNCR · Xencor, Inc. · Stock research

All prices and dates below are public market data; the reference close used throughout is the 2026-08-14 close of $23.34.

XNCR — Xencor, Inc.

Current Thesis

The July read framed Xencor as a royalty collector re-rating on hope, with two unresolved overhangs — the Ultomiris dispute and a dilution clock — and no catalyst inside 30 days. Both overhangs closed with dated events. On 2026-07-29 Xencor settled the U.S. Ultomiris royalty dispute with Alexion for $105M in two $52.5M payments, ending U.S. royalties while preserving ex-U.S. rights and extending the stated operating runway through 2028. On 2026-08-05 Q2 revenue came in at $51.2M against a $18.922M consensus and EPS at -$0.29 against -$0.79. Three price-target raises landed the next day. Price closed 2026-08-14 at $23.34, exactly the 52-week high, +108% over three months, RSI(14) 69.2. What has not changed is the shape of the story: XmAb819 expansion-cohort data at ESMO Madrid on 2026-10-23 to 10-27 is the event that decides whether the owned pipeline is worth the re-rating, and nothing dated stands between now and then.

Bullish and bearish views on Xencor, Inc.

The model's bull view on Xencor, Inc. (XNCR), in brief: The legal overhang was monetised, not litigated: 2026-07-29 settlement pays $105M in two $52.5M tranches (first anticipated August 2026, second within 14 days of the settlement's one-year anniversary), terminates U.S. Ultomiris royalties and leaves ex-U.S. royalty rights intact. The bear view: The Q2 top line is not a run-rate: the $37.3M of Ultomiris royalties inside $51.2M of revenue sits against a settlement that terminates the U.S. royalty stream going forward. Both cases follow in full.

Bull Case

• The legal overhang was monetised, not litigated: 2026-07-29 settlement pays $105M in two $52.5M tranches (first anticipated August 2026, second within 14 days of the settlement's one-year anniversary), terminates U.S. Ultomiris royalties and leaves ex-U.S. royalty rights intact. Company statement: runway extended through 2028.
• Q2 beat was wide, not marginal: revenue $51.2M vs $43.6M a year earlier and vs $18.922M consensus; net loss $21.7M / -$0.29 per share vs a $30.8M loss in Q2 2025 (reported 2026-08-05). Components: $37.3M Ultomiris royalties plus a $10M Zenas milestone on the obexelimab BLA filing.
• Sell-side re-marked in one session: on 2026-08-06 Cantor Fitzgerald raised to $44 (Overweight), Wedbush to $30 from $26 (Outperform), RBC Capital to $20 from $19 (Outperform), after Wedbush had reiterated $26 on 2026-07-30 and Truist held Buy with $27 on 2026-07-07.
• The binary has a stage and a date: XmAb819 (ENPP3 × CD3 bispecific) Phase 1 results were accepted for a proffered-paper oral presentation at ESMO 2026, Madrid, 2026-10-23 to 10-27 (announced 2026-07-17), framed by management as supporting a first pivotal study in 2027.
• Second shot on goal is enrolling: the global Phase 2b XENITH-UC study of XmAb942 (TL1A) in ulcerative colitis is enrolling ~220 patients across three active arms and placebo, primary endpoint clinical remission by modified Mayo score at week 12, with a blinded interim analysis guided around year-end 2026 and primary results in 2H 2027. TL1A M&A comparables: Merck/Prometheus ~$10.8B and Roche/Telavant ~$7.1B, both 2023.
• Pipeline breadth added in the quarter: XmAb541 received Fast Track designation in July 2026 in germ cell tumors; XmAb412 entered first-in-human study.

Bear Case

• The Q2 top line is not a run-rate: the $37.3M of Ultomiris royalties inside $51.2M of revenue sits against a settlement that terminates the U.S. royalty stream going forward. The comparison base for Q3 and beyond is ex-U.S. royalties plus milestones, and the market has not yet seen that number.
• Spend is heavy against the cash pile: Q2 R&D $71.9M and G&A $16.4M against cash and marketable securities of $486.4M at 2026-06-30 (before the first $52.5M tranche). The 10-Q language is "sufficient to fund operations for at least the next twelve months."
• The share count moved: 74,353,397 shares outstanding as of 2026-07-31 versus roughly 71.9M at year-end 2025.
• Part of the sell-side did not follow the price: RBC's raised target of $20 (2026-08-06) sits below the 2026-08-14 close of $23.34, and the visible band across recent notes runs $20 to $44.
• The science is still Phase 1: XmAb819 has no randomized comparator, and single-arm T-cell-engager data in solid tumors carries a long history of cytokine-release toxicity and modest confirmed response rates. An oral slot signals selection, not efficacy.
• Nothing dated inside 30 days: the run from the 2026-07-17 close of $17.47 to $23.34 consumed the settlement, the print and the target raises. The next company-specific event is 68 days out.

Setup & Price Structure

• 2026-08-14 close $23.34 — 0.0% from the 52-week high, RSI(14) 69.2, three-month return +108%.
• The advance was a step function, not a drift: $17.47 close on 2026-07-17 (+16.9% that session on the ESMO acceptance) → 2026-07-29 settlement → 2026-08-05 print → 2026-08-06 target cluster → new high on 2026-08-14. Investing.com flagged a 52-week high at $21.99 earlier in August, so the high has been reset repeatedly inside two weeks.
• The pre-settlement range sat around the $17–$18 zone after the 7/17 gap, with the earlier July consolidation shelf roughly $14.69–$15.72. That $18 area is the first structural floor that would mark the whole post-settlement advance as retraced.
• The narrative is accelerating. What dates it: three separate price-target revisions on a single day (2026-08-06), two fundamental headlines inside eighteen days (07-29, 08-05), and price printing new 52-week highs as recently as 2026-08-14. RBC's $20 mark below spot indicates at least one desk has not re-underwritten the post-settlement story — participation is still widening rather than exhausted.
• Crowding and positioning observables (stated, not judged): price 0.0% below its 52-week high; RSI(14) 69.2; three same-day target raises after the print; share count up ~2.4M over seven months to 74,353,397; no earnings date inside 30 days (Q2 printed 2026-08-05); and the 2026-07-20 gainers-list appearance grouped XNCR with IREN, HUT, CIFR, CLSK, APLD and AMC, which places part of the marginal bid in a high-beta momentum screen rather than an oncology cohort.

Catalyst Calendar (next 30 days)

• No dated company catalyst falls between 2026-08-16 and 2026-09-15. That absence is itself the structural fact for the window.
• ~2026-08-31 (est.) — first $52.5M Alexion tranche, "anticipated in August 2026" per the 2026-07-29 settlement terms. Cash confirmation, not a market event.
• 2026-09-25 — ESMO posts accepted late-breaking abstract titles in the online programme (regular-abstract titles were posted 2026-07-17). Just outside the 30-day window.
• 2026-10-23 to 2026-10-27 — ESMO Congress, Madrid: XmAb819 proffered-paper oral presentation. The binary.
• ~2026-11-04 (est.) — Q3 2026 results; first quarter reported after U.S. Ultomiris royalties terminate.
• ~year-end 2026 (est.) — XENITH-UC blinded interim analysis for XmAb942.

What Would Change Our Mind

The cleanest break is the ESMO slot coming and going without numbers: an XmAb819 oral on 2026-10-23 to 10-27 that shows response rates or durability too thin to support the stated 2027 pivotal start, or that lands with dose-limiting cytokine-release toxicity, removes the asset the re-rating was underwritten on. A Q3 print (~2026-11-04, est.) that shows ex-U.S. royalty revenue materially below the $37.3M booked in Q2 would confirm the top-line step-down the settlement created. On price, a weekly close below $18 retraces the entire post-settlement, post-print advance back into the pre-2026-07-17 range and ends the momentum leg on the chart; a further loss of the $14.69–$15.72 early-July shelf would break the higher-low sequence off the $6.92 low. Evidence pointing the other way — an equity raise announced while the stock is near highs, or the second $52.5M tranche failing to appear on schedule in 2027 — works on the funding leg independently of the chart.

Correlation Notes

• SMID biotech beta: XBI and IBB drawdowns move unprofitable, pre-revenue-transition names like this before any company-specific news does; a rate-driven risk-off is the most likely source of a price break unconnected to the pipeline.
• TL1A class read-across: data or regulatory events from Merck's tulisokibart (Prometheus) and Roche's RVT-3101 (Telavant) reprice the whole TL1A complex, including XmAb942's perceived partnering value.
• Bispecific T-cell-engager read-across in solid tumors: CRS or efficacy disappointments at any ENPP3/CD3-class or solid-tumor TCE competitor bleed into how ESMO expectations are set.
• Momentum-screen flow: the 2026-07-20 grouping with crypto miners and AMC means a slice of the bid tracks high-beta retail rotation, which correlates with the miners and meme complex rather than with oncology peers.
• Zenas BioPharma: obexelimab regulatory progress is a direct milestone line for Xencor — the $10M booked in Q2 2026 followed the BLA filing.
• AstraZeneca/Alexion: ex-U.S. Ultomiris sales still drive the surviving royalty line, so Alexion's franchise trajectory remains a residual revenue input.